Patient Characteristics at Study Entry
| Parameter . | Patients . | |
|---|---|---|
| No. . | % . | |
| No. of CLL patients | 122 | 100 |
| Sex | ||
| Female | 51 | 42 |
| Male | 71 | 58 |
| Age (yr) | ||
| Mean ± SEM | 58.7 ± 8.5 | |
| Range | 35-75 | |
| Time from diagnosis to study entry, mean ± SD (mo) | 30.8 ± 5.2 | |
| Performance status (ECOG score) | ||
| 0 | 89 | |
| 1 | 32 | |
| Therapy during study | ||
| None | 104 | 85.2 |
| Interferon-alfa 2b | 18 | 14.8 |
| Other | 0 | 0 |
| Lymphoid marrow infiltration as evaluated by bone marrow histology | ||
| Nodular | 37 | 30.3 |
| Nonnodular | 69 | 56.6 |
| Not evaluated at study entry | 16 | 13.1 |
| Parameter . | Patients . | |
|---|---|---|
| No. . | % . | |
| No. of CLL patients | 122 | 100 |
| Sex | ||
| Female | 51 | 42 |
| Male | 71 | 58 |
| Age (yr) | ||
| Mean ± SEM | 58.7 ± 8.5 | |
| Range | 35-75 | |
| Time from diagnosis to study entry, mean ± SD (mo) | 30.8 ± 5.2 | |
| Performance status (ECOG score) | ||
| 0 | 89 | |
| 1 | 32 | |
| Therapy during study | ||
| None | 104 | 85.2 |
| Interferon-alfa 2b | 18 | 14.8 |
| Other | 0 | 0 |
| Lymphoid marrow infiltration as evaluated by bone marrow histology | ||
| Nodular | 37 | 30.3 |
| Nonnodular | 69 | 56.6 |
| Not evaluated at study entry | 16 | 13.1 |